Tonix Pharmaceuticals (TNXP) Short Interest Ratio & Short Volume $0.19 +0.00 (+1.07%) (As of 11:52 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Tonix Pharmaceuticals Short Interest DataTonix Pharmaceuticals (TNXP) has a short interest of 5.22 million shares, representing 2.79% of the float (the number of shares available for trading by the public). This marks a -31.94% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 14.15 million shares to cover all short positions.Current Short Interest5,220,000 sharesPrevious Short Interest7,670,000 sharesChange Vs. Previous Month-31.94%Dollar Volume Sold Short$684,342.00Short Interest Ratio0.1 Days to CoverLast Record DateNovember 15, 2024Outstanding Shares186,890,000 sharesFloat Size186,890,000 sharesShort Percent of Float2.79%Today's Trading Volume17,017,677 sharesAverage Trading Volume14,148,958 sharesToday's Volume Vs. Average120% Short Selling Tonix Pharmaceuticals? Sign up to receive the latest short interest report for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTNXP Short Interest Over TimeTNXP Days to Cover Over TimeTNXP Percentage of Float Shorted Over Time Ad Darwin"Start Earning Extra Income with Just $30"What if you could unlock a steady income stream from stocks priced under $30? Our new guide walks you through simple, effective options strategies designed for everyday investors. With step-by-step insights, you’ll learn how to transform familiar names like Ford and Intel into reliable monthly income generators.Claim Your Free Report Now: “Options Made Simple – 2 Affordable Stocks for Monthly Income” Tonix Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/15/20245,220,000 shares $684,342.00 -31.9%2.8%0.1 $0.13 10/31/20247,670,000 shares $1.11 million +40.5%5.6%0.2 $0.15 10/15/20245,460,000 shares $769,860.00 -34.1%4.0%0.2 $0.14 9/30/20248,290,000 shares $1.23 million +1,674.4%6.0%0.3 $0.15 9/15/2024467,200 shares $73,256.96 -70.2%0.3%0 $0.16 8/31/20241,570,000 shares $359,530.00 +20.8%7.1%0.1 $0.23 Get the Latest News and Ratings for TNXP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/15/20241,300,000 shares $593,840.00 +132.0%5.9%0.1 $0.46 7/31/2024560,400 shares $278,014.44 +30.5%2.7%0.3 $0.50 7/15/2024429,600 shares $256,385.28 -76.0%2.5%0.3 $0.60 6/30/20241,790,000 shares $1.25 million +1.7%18.2%1.6 $0.70 6/15/20241,760,000 shares $2.02 million +7,025.5%58.9%3.8 $1.15 5/31/202424,700 shares $128,756.16 -96.9%0.8%0.2 $5.21 5/15/2024785,600 shares $143,450.56 -50.9%0.8%0.3 $0.18 4/30/20241,600,000 shares $287,040.00 +7.4%1.9%0.7 $0.18 4/15/20241,490,000 shares $217,391.00 +19.2%1.8%0.7 $0.15 3/31/20241,250,000 shares $232,500.00 +29.3%1.5%0.6 $0.19 3/15/2024967,000 shares $310,407.00 +56.9%1.2%0.6 $0.32 2/29/2024616,200 shares $233,046.84 +3.3%0.8%0.3 $0.38 2/15/2024596,500 shares $230,249.00 -6.5%0.7%0.3 $0.39 1/31/2024638,200 shares $204,224.00 +132.1%0.8%0.4 $0.32 1/15/2024275,000 shares $81,455.00 -20.4%0.3%0.2 $0.30 12/31/2023345,300 shares $139,155.90 -77.0%0.6%0.3 $0.40 12/15/20231,500,000 shares $857,700.00 +308.7%5.6%1.4 $0.57 11/30/2023367,000 shares $190,106.00 +270.0%1.5%0.7 $0.52 11/15/202399,200 shares $46,723.20 -70.1%0.4%0.3 $0.47 10/31/2023331,600 shares $195,644.00 +21.2%1.2%1.1 $0.59 10/15/2023273,600 shares $159,727.68 -31.4%1.0%0.6 $0.58 9/30/2023398,700 shares $217,291.50 +277.9%2.3%0.9 $0.55 9/15/2023105,500 shares $97,060.00 -65.5%0.6%0.3 $0.92 8/31/2023305,600 shares $295,331.84 -33.3%1.7%0.7 $0.97 8/15/2023458,200 shares $439,093.06 -71.5%2.6%1 $0.96 7/31/20231,610,000 shares $1.72 million +12.6%15.0%3.4 $1.07 7/15/20231,430,000 shares $2.52 million -4.7%13.9%5.3 $1.76 6/30/20231,500,000 shares $2.37 million +32.7%14.5%5.5 $1.58 6/15/20231,130,000 shares $2.17 million +13.4%11.0%4.5 $1.92 5/31/2023996,900 shares $1.78 million +56.1%9.7%4.5 $1.79 5/15/2023638,800 shares $1.23 million +167.6%6.2%2.9 $1.92 4/30/20231,490,000 shares $774,800.00 +2.8%2.4%1.3 $0.52 4/15/20231,450,000 shares $745,445.00 -42.0%2.3%1 $0.51 3/31/20232,500,000 shares $1.48 million -18.6%4.0%0.9 $0.59Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 3/15/20233,070,000 shares $1.73 million +15.9%4.9%0.8 $0.56 2/28/20232,650,000 shares $1.86 million -27.0%4.4%0.4 $0.70 2/15/20233,630,000 shares $3.88 million -14.6%6.0%0.5 $1.07 1/31/20234,250,000 shares $4.76 million -24.9%7.4%0.6 $1.12 1/15/20235,660,000 shares $7.36 million +68.5%9.8%0.9 $1.30 12/30/20223,360,000 shares $1.31 million -21.5%5.8%0.6 $0.39 12/15/20224,280,000 shares $1.39 million +210.1%7.4%1 $0.33 11/30/20221,380,000 shares $531,300.00 +123.2%2.4%0.8 $0.39 11/15/2022618,200 shares $306,009.00 -34.6%1.1%0.3 $0.50 10/31/2022945,400 shares $426,375.40 -16.3%1.7%0.4 $0.45 10/15/20221,130,000 shares $541,835.00 +1.8%2.5%0.2 $0.48 9/30/20221,110,000 shares $592,962.00 -41.6%2.5%0.2 $0.53 9/15/20221,900,000 shares $1.64 million -20.8%4.2%0.3 $0.86 8/31/20222,400,000 shares $2.45 million -4.0%5.4%0.3 $1.02 8/15/20222,500,000 shares $3.98 million +5.9%5.7%0.2 $1.59 7/31/20222,360,000 shares $3.96 million +204.6%7.5%0.2 $1.68 7/15/2022774,800 shares $983,996.00 -28.9%2.5%0.1 $1.27 6/30/20221,090,000 shares $1.72 million -30.1%5.8%0.2 $1.58 6/15/20221,560,000 shares $2.78 million -54.5%8.3%0.3 $1.78 5/31/20223,430,000 shares $8.37 million +133.3%18.3%0.6 $2.44 5/15/20221,470,000 shares $6.21 million -96.7%7.9%0.8 $4.22 4/30/202245,070,000 shares $6.58 million +21.8%N/A1.6 $0.15 4/15/202237,000,000 shares $6.95 million +15.6%N/A1.3 $0.19 3/31/202232,010,000 shares $7.37 million +11.1%N/A1.1 $0.23 3/15/202228,820,000 shares $6.14 million +2.2%N/A1.1 $0.21 2/28/202228,200,000 shares $5.22 million +2.6%N/A1.1 $0.19 2/15/202227,480,000 shares $5.69 million +19.5%N/A1.5 $0.21 1/31/202223,000,000 shares $5.59 million +167.8%N/A1.3 $0.24 1/15/20228,590,000 shares $2.46 million -14.2%N/A0.5 $0.29 12/31/202110,010,000 shares $3.58 million +15.5%N/A0.6 $0.36 12/15/20218,670,000 shares $3.80 million +0.2%N/A0.5 $0.44 11/30/20218,650,000 shares $4.06 million +39.1%N/A0.5 $0.47 11/15/20216,220,000 shares $3.60 million -0.5%N/A0.4 $0.58 10/29/20216,250,000 shares $3.45 million -0.3%N/A0.5 $0.55 10/15/20216,270,000 shares $3.57 million -33.8%N/A0.5 $0.57 9/30/20219,470,000 shares $5.69 million -4.6%N/A0.8 $0.60 9/15/20219,930,000 shares $6.16 million -15.4%N/A0.8 $0.62 8/31/202111,730,000 shares $8.28 million -15.7%N/A1.1 $0.71 8/13/202113,920,000 shares $9.47 million -12.8%N/A1.2 $0.68 7/30/202115,960,000 shares $11.43 million +36.9%4.8%1.5 $0.72 7/15/202111,660,000 shares $11.50 million -35.6%3.5%1.1 $0.99 6/30/202118,110,000 shares $20.10 million +115.3%5.5%1.7 $1.11 6/15/20218,410,000 shares $11.19 million +44.8%2.6%0.8 $1.33 5/28/20215,810,000 shares $6.86 million +10.3%1.8%0.4 $1.18 5/14/20215,270,000 shares $5.11 million -7.4%N/A0.4 $0.97 4/30/20215,690,000 shares $6.54 million +24.5%N/A0.2 $1.15 4/15/20214,570,000 shares $4.98 million -18.8%N/A0.1 $1.09 3/31/20215,630,000 shares $7.04 million +44.0%N/A0.1 $1.25 3/15/20213,910,000 shares $4.97 million +132.7%N/A0.1 $1.27 2/26/20211,680,000 shares $2.05 million -64.6%N/A0 $1.22Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. 2/12/20214,740,000 shares $9.48 million +57.0%N/A0.1 $2.00 1/29/20213,020,000 shares $2.96 million -31.8%N/A0.1 $0.98 1/15/20214,430,000 shares $4.24 million +58.2%N/A0.2 $0.96 12/31/20202,800,000 shares $1.91 million +388.5%N/A0.2 $0.68 12/15/2020573,200 shares $333,602.40 +31.6%N/A0.1 $0.58 11/30/2020435,500 shares $249,106.00 -45.0%N/A0.1 $0.57 11/15/2020791,500 shares $489,067.85 +1.3%N/A0.1 $0.62 10/30/2020781,000 shares $470,630.60 -19.1%N/A0.1 $0.60 10/15/2020964,900 shares $713,157.59 -2.8%N/A0.1 $0.74 9/30/2020992,600 shares $833,784.00 -48.6%N/A0 $0.84 9/15/20201,930,000 shares $1.55 million +25.3%N/A0.1 $0.80 8/31/20201,540,000 shares $1.36 million -16.8%N/A0.1 $0.89 8/14/20201,850,000 shares $1.89 million -35.8%N/A0.1 $1.02 7/31/20202,880,000 shares $3.72 million +100.0%N/A0.1 $1.29 7/15/20201,440,000 shares $819,360.00 -4.6%N/A0.1 $0.57 6/30/20201,510,000 shares $921,855.00 +100.9%N/A0.2 $0.61 6/15/2020751,600 shares $464,488.80 +46.3%N/A0.1 $0.62 5/29/2020513,800 shares $347,482.94 -44.8%N/A0.1 $0.68 5/15/2020931,300 shares $639,989.36 +135.6%N/A0.1 $0.69 4/30/2020395,300 shares $266,155.49 -49.2%N/A0 $0.67 4/15/2020778,700 shares $595,705.50 -58.6%N/A0.1 $0.77 3/31/20201,880,000 shares $1.30 million +1.2%N/A0.2 $0.69 3/13/20201,856,900 shares $1.34 million -43.6%21.8%0.2 $0.72 2/28/20203,290,000 shares $2.80 million +2,138.1%38.6%0.4 $0.85 2/14/2020147,000 shares $124,950.00 -69.6%1.7%0 $0.85 1/31/2020482,900 shares $434,610.00 -44.4%5.7%0.2 $0.90 1/15/2020868,700 shares $416,976.00 +741.8%10.2%0.5 $0.48 12/31/2019103,200 shares $168,216.00 -66.6%1.2%0.1 $1.63 TNXP Short Interest - Frequently Asked Questions What is Tonix Pharmaceuticals' current short interest? Short interest is the volume of Tonix Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of November 15th, investors have sold 5,220,000 shares of TNXP short. 2.79% of Tonix Pharmaceuticals' shares are currently sold short. Learn More on Tonix Pharmaceuticals' current short interest. What is a good short interest percentage for Tonix Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.79% of Tonix Pharmaceuticals' floating shares are currently sold short. Is Tonix Pharmaceuticals' short interest increasing or decreasing? Tonix Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 5,220,000 shares, a decrease of 31.9% from the previous total of 7,670,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Tonix Pharmaceuticals' float size? Tonix Pharmaceuticals currently has issued a total of 186,890,000 shares. Some of Tonix Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Tonix Pharmaceuticals currently has a public float of 186,890,000 shares. How does Tonix Pharmaceuticals' short interest compare to its competitors? 2.79% of Tonix Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Tonix Pharmaceuticals: Acumen Pharmaceuticals, Inc. (3.26%), Inventiva S.A. (0.74%), InflaRx (0.28%), Skye Bioscience, Inc. (11.33%), Vaxart, Inc. (5.04%), Repare Therapeutics Inc. (2.12%), Compugen Ltd. (1.48%), Cidara Therapeutics, Inc. (0.92%), Cardiff Oncology, Inc. (15.10%), Cardiol Therapeutics Inc. (1.16%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($4.85 billion), Charter Communications, Inc. ($4.81 billion), International Paper ($2.96 billion), Cencora, Inc. ($2.40 billion), Paychex, Inc. ($2.38 billion), Lululemon Athletica Inc. ($2.05 billion), SoFi Technologies, Inc. ($2.03 billion), Live Nation Entertainment, Inc. ($1.93 billion), Onsemi ($1.82 billion), and Tractor Supply ($1.65 billion). View all of the most shorted stocks. What does it mean to sell short Tonix Pharmaceuticals stock? Short selling TNXP is an investing strategy that aims to generate trading profit from Tonix Pharmaceuticals as its price is falling. TNXP shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Tonix Pharmaceuticals? A short squeeze for Tonix Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TNXP, which in turn drives the price of the stock up even further. How often is Tonix Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TNXP, twice per month. The most recent reporting period available is November, 15 2024. More Short Interest Resources from MarketBeat Related Companies ABOS Short Interest Data IVA Short Interest Data IFRX Short Interest Data SKYE Short Interest Data VXRT Short Interest Data RPTX Short Interest Data CGEN Short Interest Data CDTX Short Interest Data CRDF Short Interest Data CRDL Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TNXP) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
